2024-04-15 16:08:10 ET
Summary
- Given the huge and growing GLP-1 weight loss market, recent trial data from Viking Therapeutics could make it a potential acquisition target for a larger concern.
- While many bigger pharma names might desire entry into the huge GLP-1 weight loss market, Pfizer makes logical sense on several fronts.
- We discuss the potential of such a combination and offer up several reasons Pfizer would want to at least "kick the tires" on Viking Therapeutics in the paragraphs below.
We're going to engage in some buyout speculation, which is one of the main drivers for the biotech sector. When M&A volume is high, the sector tends to go up. When deal volume is punk, trading action tends to be tepid. In this column, we are going to tee up a potential acquisition of midcap biopharma concern Viking Therapeutics ( VKTX ) by one of the gianta in the pharma space, Pfizer ( PFE ) . ...
Read the full article on Seeking Alpha
For further details see:
Pfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A Talk